Clinical Trial Update: Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Epigallocatechin gallate (EGCG) for cardiac AL amyloidosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis
• Cardiac Amyloidosis

Drugs mentioned

• Epigallocatechin Gallate (EGCG) (epigallocatechin gallate)

Snippet

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia | Conditions: Primary Amyloidosis of Light Chain Type | Phase 2 | Status: TERMINATED